Literature DB >> 2888874

Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.

P K Sonsalla1, S K Youngster, M V Kindt, R E Heikkila.   

Abstract

1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP) was shown previously to be a more potent neurotoxicant than 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. The present investigation was conducted to determine possible reasons for the greater potency of 2'CH3-MPTP and to determine if its neurotoxic action might be similar to that of MPTP. 2'CH3-MPTP was a much better substrate for monoamine oxidase than was MPTP (Km values of 66 and 114 microM and Vmax values of 3433 and 1389 nmol/g of tissue per hr for 2'CH3-MPTP and MPTP, respectively) and it is likely that this is an important feature which contributes to its greater potency. In addition, its pyridinium metabolite, 1-methyl-4-(2'-methylphenyl)pyridinium was found to be an excellent substrate for the dopamine carrier with Km and Vmax values (513 nM and 4.1 nmol/g of tissue per min, respectively) similar to those of 1-methyl-4-phenylpyridinium (872 nM and 5.2 nmol/g of tissue per min, respectively). In vivo, 2'CH3-MPTP-induced neurotoxicity, like MPTP-induced neurotoxicity, was attenuated by the pretreatment of mice with a dopamine uptake inhibitor (mazindol or GBR 13069). However, selective doses of the monoamine oxidase (MAO)-B inhibitors, deprenyl or MDL 72145, failed to prevent in vivo neurotoxicity induced by 2'CH3-MPTP although these doses effectively blocked MPTP-induced neurotoxicity. Protection against 2'CH3-MPTP-induced neurotoxicity was observed only at a nonselective dose of MDL 72145 which blocked both MAO-B and MAO-A activities.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888874

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins.

Authors:  Bryan Lickteig; Virangika K Wimalasena; Kandatege Wimalasena
Journal:  ACS Chem Neurosci       Date:  2019-04-10       Impact factor: 4.418

2.  Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.

Authors:  Kang-Woo Lee; Joo-Young Im; Jong-Min Woo; Hilary Grosso; Yoon-Seong Kim; Ana Clara Cristovao; Patricia K Sonsalla; David S Schuster; Marla M Jalbut; Jose R Fernandez; Michael Voronkov; Eunsung Junn; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 3.  The challenge of mechanism-based modeling in risk assessment for neurobehavioral end points.

Authors:  D Hattis
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

4.  Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.

Authors:  Emilie Cornille; Mhamad Abou-Hamdan; Michel Khrestchatisky; André Nieoullon; Max de Reggi; Bouchra Gharib
Journal:  BMC Neurosci       Date:  2010-04-23       Impact factor: 3.288

5.  The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.

Authors:  Patricia K Sonsalla; Lai-Yoong Wong; Bozena Winnik; Brian Buckley
Journal:  Exp Neurol       Date:  2009-12-04       Impact factor: 5.330

6.  Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  R E Heikkila; M V Kindt; P K Sonsalla; A Giovanni; S K Youngster; K A McKeown; T P Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH3-MPTP: A Novel Approach.

Authors:  Alice Laschuk Herlinger; Agihane Rodrigues Almeida; Sarah Martins Presti-Silva; Evaldo Vitor Pereira; Filipe Andrich; Rita Gomes Wanderley Pires; Cristina Martins-Silva
Journal:  Neuromolecular Med       Date:  2018-01-13       Impact factor: 3.843

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.